TABLE 3.
Distribution of vaccine‐antigen genotype combinations, 2018–2024
| 2018 | 2019 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| ptxC2/prn150/ptxP3/fhaB2400_5550-1/tcfA2 | 0 | 3 (11.54%) | 29 (82.86%) | 26 (96.30%) | 11 (100%) | 54 (98.18%) |
| ptxC2/prn2/ptxP3/fhaB2400_5550-1/tcfA2 | 8 (33.33%) | 10 (38.46%) | 2 (5.71%) | 0 | 0 | 1 (1.82%) |
| ptxC1/prn1/ptxP1/fhaB2400_5550-3/tcfA2 | 13 (54.17%) | 11 (42.31%) | 3 (8.57%) | 1 (3.7%) | 0 | 0 |
| ptxC1/prn166/ptxP1/fhaB2400_5550-3/tcfA2 | 1 (4.17%) | 2 (7.69%) | 0 | 0 | 0 | 0 |
| ptxC2/prn149/ptxP3/fhaB2400_5550-1/tcfA2 | 2 (8.33%) | 0 | 0 | 0 | 0 | 0 |
| ptxC2/prn150/ptxP3/fhaB2400_5550-1/tcfA9 | 0 | 0 | 1 (2.86%) | 0 | 0 | 0 |